Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model

Pradas, R.; Miguel, Ángel Gil de; Álvaro, Alejandro; Gil-Prieto, Ruth; Lorente, Reyes; Méndez, Cristina; Guijarro, Pablo; Antoñanzas, Fernando

doi:10.1186/1471-2334-13-175

Cited by 21 publications

(42 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rozenbaum et al (Netherlands), 32 categorized IPD disease into meningitis, bactaeremic pneumonia, and bactaeremic without focus. Pradas et al 33 used a similar approach, stratifying IPD into primary bacteremia, empyema, meningitis, and bactaeremic pneumonia.…”

Section: Disease States and Outcomesmentioning

confidence: 99%

“…39 In terms of the type of economic evaluation, 7 publications were cost-utility analyses, presenting cost per Quality Adjusted Life Year (QALY) gained as the primary outcome. 24,[26][27][28][29]31,32 Whereas the studies by Liguori et al 30 and Pradas et al 33 could be classified as cost-effectiveness analyses, calculating the cost per case of pneumococcal disease avoided as the main outcome. …”

Section: Economic Evaluation Modelmentioning

confidence: 99%

“…32 Likewise, in Italy and Spain, although the PPV23 vaccine is recommended for those 65 and high risk 2 y, the coverage rate remains low. 29,30,33 Italy and Spain (partially) have also already introduced PCV13 to their vaccination programs, whereas in the Netherlands, PCV7 was introduced at 2006 and from 2011 PCV10 and PCV13 were available for infants.…”

Section: Setting and Intervention Evaluatedmentioning

confidence: 99%

“…[24][25][26][27][28] two were conducted for Italy 29,30 and the remaining 3 were performed for England, the Netherlands and Spain respectively. [31][32][33] Of the 5 US publications, 3 were authored by Smith et al 24,26,27 with 2 others by Weycker et al and…”

Section: Setting and Intervention Evaluatedmentioning

confidence: 99%

“…Most of the studies used a Markov (or Markov-type ) model 38 to evaluate the cost-effectiveness of the PCV13 in adults except Pradas et al who applied a dynamic model 33 ( Table 1). Dynamic models can explicitly capture herd immunity effects, by allowing infection risks to vary proportional with the infectious prevalence and modeling population immunity.…”

Section: Economic Evaluation Modelmentioning

confidence: 99%

See 4 more Smart Citations

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly

Dirmesropian

Wood

MacIntyre

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The 13-valent pneumococcal conjugated vaccine (PCV13) is already recommended for some adult groups and is being considered for wider use in many countries. In order to identify the strengths and limitations of the existing economic evaluation studies of PCV13 in adults and the elderly a literature review was conducted. The majority of the studies identified (9 out of 10) found that PCV13 was costeffective in adults and/or the elderly. However, these results were based on assumptions that could not always be informed by robust evidence. Key uncertainties included the efficacy of PCV13 against non-invasive pneumonia and the herd immunity effect of childhood vaccination programs. Emerging trial evidence on PCV13 in adults from the Netherlands offers the ability to parameterize future economic evaluations with empirical efficacy data. However, it is important that these estimates are used thoughtfully when they are transferred to other settings.

show abstract

Section: Disease States and Outcomesmentioning

confidence: 99%

Section: Economic Evaluation Modelmentioning

confidence: 99%

Section: Setting and Intervention Evaluatedmentioning

confidence: 99%

Section: Setting and Intervention Evaluatedmentioning

confidence: 99%

Section: Economic Evaluation Modelmentioning

confidence: 99%

See 3 more Smart Citations

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly

Dirmesropian

Wood

MacIntyre

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

Recommendations for Pneumococcal Immunization Outside Routine Childhood Immunization Programs in Western Europe

Castiglia

2014

Adv Ther

View full text Add to dashboard Cite

The global burden of pneumococcal diseases is high, with young children and adults ≥50 years of age at highest risk of infection. Two types of vaccine are available for the prevention of pneumococcal diseases caused by specific Streptococcus pneumoniae serotypes: the pneumococcal polysaccharide vaccine (PPV23) and the pneumococcal conjugate vaccine (PCV7, PCV10, and PCV13). Despite pneumococcal immunization programs in adults and children, the burden in adults has remained high. Most European countries have national or local/regional vaccination recommendations. The objective of this review was to provide an overview of the government recommendations for pneumococcal vaccination outside routine childhood vaccination programs for 16 Western European countries as of August 2014. We found that recommendations for pneumococcal immunization across Europe are complex and vary greatly among countries in terms of age groups and risk groups recommended for vaccination, as well as which vaccine should be administered. Clarifying or simplifying these recommendations and improving their dissemination could help to increase pneumococcal vaccine uptake and decrease the high burden of pneumococcal diseases in adults, both through a direct effect of the vaccine and via a herd effect in unvaccinated individuals.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-014-0157-1) contains supplementary material, which is available to authorized users.

show abstract

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundPatients with chronic obstructive pulmonary disease (COPD) are at elevated risk of pneumococcal infection. A 13-valent pneumococcal conjugate vaccine (PCV13) was approved for protection against invasive disease and pneumonia caused by Streptococcus pneumoniae in adults. This study estimated the incremental cost-effectiveness ratio (ICER) of vaccinating COPD patients ≥50 years old with PCV13 compared with current vaccination policy (CVP) with 23-valent pneumococcal polysaccharide vaccine.MethodsA Markov model accounting for the risks and costs for all-cause non-bacteremic pneumonia (NBP) and invasive pneumococcal disease (IPD) was developed. All parameters, such as disease incidence and costs (€; 2015 values), were based on published data. The perspective of the analysis was that of the Spanish National Healthcare System, and the horizon of evaluation was lifetime in the base case. Vaccine effectiveness considered waning effect over time. Outcomes and costs were both discounted by 3 % annually.ResultsOver a lifetime horizon and for a 629,747 COPD total population, PCV13 would prevent 2224 cases of inpatient NBP, 3134 cases of outpatient NBP, and 210 IPD extra cases in comparison with CVP. Additionally, 398 related deaths would be averted. The ICER was €1518 per quality-adjusted life-year (QALY) gained for PCV13 versus CVP. PCV13 was found to be cost effective versus CVP from a 5-year modelling horizon (1302 inpatient NBP and 1835 outpatient NBP cases together with 182 deaths would be prevented [ICER €25,573/QALY]). Univariate and probabilistic sensitivity analyses confirmed the robustness of the model.ConclusionsAt the commonly accepted willingness-to-pay threshold of €30,000/QALY gained, PCV13 vaccination in COPD patients aged ≥50 years was a cost-effective strategy compared with CVP from 5 years to lifetime horizon in Spain.

show abstract

Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model

Cited by 21 publications

References 21 publications

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly

Recommendations for Pneumococcal Immunization Outside Routine Childhood Immunization Programs in Western Europe

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain

Contact Info

Product

Resources

About